Johnson & Johnson Beats Expectations

A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake (Reuters) - Johnson & Johnson reported better-than-expected fourth-quarter revenue on Tuesday, helped by strong demand for its drugs to treat cancer and psoriasis. Overall sales rose to $20.39 billion from $20.20 billion, above the average Wall Street estimate of $20.20 billion, according to IBES data from Refinitiv.